Clinical trials · New York
Advanced Cancer clinical trials in New York
We’re tracking 270 recruiting advanced cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06590857RecruitingPhase 1/Phase 2
Study of targeted radiation for advanced breast cancer
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
Buffalo, New YorkAges Any age - NCT07818018RecruitingPhase 1/Phase 2
Study of 2141-V11 for esophageal, stomach, or junction cancer
This trial tests a new drug called 2141-V11 in people with advanced esophageal, stomach, or gastroesophageal junction cancer. It aims to see if adding this drug to your current treatment can help control the cancer better.
New York, New YorkAges 18 years+ - NCT07635147Recruiting
Decision Support Tool for Advanced Breast Cancer
This study tests a digital tool designed to help patients with advanced (stage IV) breast cancer make treatment decisions. The tool may help you understand your options and feel more confident discussing them with your doctor.
Brooklyn, New YorkAges 18 years+ - NCT07391956Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether special supportive care (called tiered palliative care) can help people with advanced heart failure or certain advanced cancers feel better and have fewer hospital visits. If you live in Manhattan or Queens, speak English or Spanish, and meet the other requirements, you may be able to join.
Astoria, New YorkAges 18 years+ - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Amsterdam, New YorkAges 18–55 - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
New York, New YorkAges 18 years+ - NCT07080242RecruitingPhase 1
Study of BL-M14D1 for small cell lung cancer and neuroendocrine tumors
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Buffalo, New YorkAges 18 years+ - NCT06963723Recruiting
Screening for financial hardship in advanced cancer
This study screens people with advanced cancer for financial problems. It aims to see if catching these problems early can improve your care and well-being.
New York, New YorkAges 21 years+ - NCT06771219RecruitingPhase 1
Testing SLV-154 for advanced cancers
This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.
New York, New YorkAges 12 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT06228209Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether adding a palliative care specialist to your regular care team can improve your quality of life if you have advanced heart failure or advanced lung or certain gastrointestinal cancers. It is for people who have been in the hospital recently and live in Manhattan.
New York, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Buffalo, New YorkAges Any age - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Buffalo, New YorkAges 18 years+ - NCT05398484RecruitingPhase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety
This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.
New York, New YorkAges 21–100 - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Lake Success, New YorkAges 18 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
New York, New YorkAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
New York, New YorkAges 12 years+ - NCT06827236RecruitingPhase 1/Phase 2
Testing a new combination treatment for advanced breast cancer
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Harrison, New YorkAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
East Syracuse, New YorkAges 18 years+ - NCT07484022RecruitingPhase 1
A new drug added to standard treatment for advanced bladder cancer
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
Lake Success, New YorkAges 18 years+ - NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
New York, New YorkAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
New York, New YorkAges 18 years+
Advanced Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting advanced cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- NYU Langone Health · 4 studies
- Columbia University Irving Medical Center · 3 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 3 studies
- Mount Sinai Health System · 3 studies
- Memorial Sloan Kettering Westchester · 2 studies
- Northwell Health · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
What taking part in a advanced cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Cancer trials in other states
Common questions
- Are there advanced cancer clinical trials in New York?
- Yes. We're currently tracking 270 recruiting advanced cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.